Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerald S Falchook

Showing results (41-50 of 136) with videos related to

Pageof 14
Sort By:
Molecular Cancer Therapeutics|May 17, 2011
Phase I trial of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel: toxicity, pharmacokinetics, and activitySiqing Fu, Aung Naing, Stacy L Moulder, et al.
Journal of Cancer Research and Clinical Oncology|March 5, 2013
Factors related to biopsy willingness in patients with advanced cancer in a phase 1 clinic for molecularly targeted therapyDavid S Hong, Goldy C George, Eucharia C Iwuanyanwu, et al.
Investigational New Drugs|April 19, 2023
A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumorsArvind Dasari, Erika P Hamilton, Gerald S Falchook, et al.
Investigational New Drugs|August 3, 2013
Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignanciesGerald S Falchook, Siqing Fu, Aung Naing, et al.
Molecular Cancer Therapeutics|August 22, 2013
Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutationsJennifer J Wheler, Apostolia M Tsimberidou, Gerald S Falchook, et al.
Targeted Oncology|November 19, 2024
Open-Label, Multicenter, Phase I Study to Assess Safety and Tolerability of Adavosertib Plus Durvalumab in Patients with Advanced Solid TumorsManish R Patel, Gerald S Falchook, Judy S Wang, et al.
Cancer Chemotherapy and Pharmacology|February 11, 2015
Phase I trial of valproic acid and lenalidomide in patients with advanced cancerMehmet Asim Bilen, Siqing Fu, Gerald S Falchook, et al.
Investigational New Drugs|March 31, 2015
Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancerDavid S Hong, Filip Janku, Aung Naing, et al.
Thyroid : Official Journal of the American Thyroid Association|October 7, 2014
BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancerGerald S Falchook, Michael Millward, David Hong, et al.
International Journal of Clinical Pharmacology and Therapeutics|June 16, 2015
Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumorsGerald S Falchook, Karthik Venkatakrishnan, John Sarantopoulos, et al.
Pageof 14

Showing results (41-50 of 136) with videos related to

Sort By:
Pageof 14
Molecular Cancer Therapeutics|May 17, 2011
Phase I trial of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel: toxicity, pharmacokinetics, and activitySiqing Fu, Aung Naing, Stacy L Moulder, et al.
Journal of Cancer Research and Clinical Oncology|March 5, 2013
Factors related to biopsy willingness in patients with advanced cancer in a phase 1 clinic for molecularly targeted therapyDavid S Hong, Goldy C George, Eucharia C Iwuanyanwu, et al.
Investigational New Drugs|April 19, 2023
A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumorsArvind Dasari, Erika P Hamilton, Gerald S Falchook, et al.
Investigational New Drugs|August 3, 2013
Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignanciesGerald S Falchook, Siqing Fu, Aung Naing, et al.
Molecular Cancer Therapeutics|August 22, 2013
Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutationsJennifer J Wheler, Apostolia M Tsimberidou, Gerald S Falchook, et al.
Targeted Oncology|November 19, 2024
Open-Label, Multicenter, Phase I Study to Assess Safety and Tolerability of Adavosertib Plus Durvalumab in Patients with Advanced Solid TumorsManish R Patel, Gerald S Falchook, Judy S Wang, et al.
Cancer Chemotherapy and Pharmacology|February 11, 2015
Phase I trial of valproic acid and lenalidomide in patients with advanced cancerMehmet Asim Bilen, Siqing Fu, Gerald S Falchook, et al.
Investigational New Drugs|March 31, 2015
Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancerDavid S Hong, Filip Janku, Aung Naing, et al.
Thyroid : Official Journal of the American Thyroid Association|October 7, 2014
BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancerGerald S Falchook, Michael Millward, David Hong, et al.
International Journal of Clinical Pharmacology and Therapeutics|June 16, 2015
Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumorsGerald S Falchook, Karthik Venkatakrishnan, John Sarantopoulos, et al.
Pageof 14